Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint Pharmaceuticals (NASDAQ: EYPT) appointed Dr. Jay S. Duker as Chief Strategic Scientific Officer to lead the development of EYP-1901, targeted at wet age-related macular degeneration. Dr. Duker, a renowned retina specialist with over 30 years of experience, will focus on advancing research and pipeline expansion while continuing to practice medicine. He steps down from the Board of Directors to take on this part-time role. The company granted him stock options for 250,000 shares as part of the inducement for his appointment.
EyePoint Pharmaceuticals (NASDAQ:EYPT) announced that CEO Nancy Lurker will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:30 AM ET. The event will be streamed live and an archived replay will be available on the company's website for 90 days. EyePoint is focused on innovative ophthalmic products addressing unmet medical needs, with two commercial products: DEXYCU and YUTIQ. Their pipeline includes EYP-1901, a VEGF inhibitor aimed at treating various serious eye disorders. For more information, visit www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced positive retrospective case study results for DEXYCU® (dexamethasone intraocular suspension) 9% aimed at treating post-operative inflammation after ocular surgeries. Presented at ASCRS 2020, interim data included significant improvements in inflammation metrics among patients. With a projected enrollment of 600 patients, the study confirms DEXYCU's efficacy over traditional steroid drops, enhancing patient adherence and minimizing hospital visits amid pandemic concerns. The findings bolster the perceived advantages of DEXYCU in clinical settings.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported total revenues of $7.5 million for Q1 2020, up from $2.0 million in Q1 2019. Net product revenues reached $4.7 million, driven primarily by $3.6 million from YUTIQ and $1.1 million from DEXYCU. Operating expenses increased to $18.9 million, leading to a net loss of $13.2 million or $0.11 per share. The company has initiated GLP toxicology studies for its EYP-1901 treatment and expects to file an IND application later this year. Cash reserves stand at $26.3 million, supporting operations amid COVID-19 challenges.